Home-based pulmonary rehabilitation in patients undergoing (chemo)radiation therapy for unresectable lung cancer: a prospective explorative study
-
Published:2022-10-10
Issue:12
Volume:127
Page:1322-1332
-
ISSN:1826-6983
-
Container-title:La radiologia medica
-
language:en
-
Short-container-title:Radiol med
Author:
Borghetti Paolo, Branz Jacopo, Volpi GiuliaORCID, Pancera Simone, Buraschi Riccardo, Bianchi Luca Nicola Cesare, Bonù Marco Lorenzo, Greco Diana, Facheris Giorgio, Tomasi Cesare, Pini Laura, Bezzi Michela, Grisanti Salvatore, Gallazzi Maria Sole, Borghesi Andrea, Buglione di Monale e Bastia Michela,
Abstract
Abstract
Aims
The prevention of pulmonary toxicity is an important goal for patient candidate to radiation therapy for lung cancer. There is a lack of evidence on the role of exercise training for patients with unresectable stage III lung cancer candidated to radical treatment. The aim of this study was to evaluate the feasibility of a home-based pulmonary rehabilitation (PR) program and to identify reliable tools in terms of respiratory function, exercise capacity and quality of life.
Methods
Patients’ recruitment lasted from April 2020 till February 2022. The PR program was proposed concomitantly to radiation therapy to the first 20 patients (interventional group, IG), and the other 20 patients were identified as an observational group (OG). All patients were assessed at baseline (T0) and after 8 weeks (T2) with 6 minute walking test (6MWT), modified Borg Scale (mBORG), SF-36 questionnaire (SF-36) and pulmonary function test (PFT); after 4 weeks (T1), only SF-36 was administered.
Results
A decrease of 13.8 m in the walked-distance was registered in the OG between T0 and T2 (p = 0.083). Instead, an increase of 56.6 m in the distance walked was recorded in the IG between T0 and T2 (p ≤ 0.001).
In the OG, the mBORG scores showed a negative trend. On the contrary, in the IG, these scores showed a slight improvement. In the OG, all the items of SF-36 scores decreased between T0 and T1. In the IG, an increased trend from T0 to T2 was observed for all the items of SF-36. No clinically significant variations were detected from baseline to T2 in both groups regarding PFT.
Conclusion
The 6MWT, mBORG and SF-36 resulted as useful tools to assess the role of a PR program. A significant gain in functional exercise capacity and a prevention of the physiological impairment of QoL during radio(chemo)therapy was registered.
Funder
Università degli Studi di Brescia
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,General Medicine
Reference40 articles.
1. “Key statistics for lung cancer”; American Cancer Society. 2022. https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html 2. Ganti AK, Klein AB, Cotarla I, Seal B, Chou E (2021) Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US. JAMA Oncol 7(12):1824–1832. https://doi.org/10.1001/jamaoncol.2021.4932 3. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro CJ, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M (2017) PACIFIC investigators durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 377(20):1919–1929. https://doi.org/10.1056/NEJMoa1709937 4. Socinski MA, Kahl KL (2021) Epidemiology and Clinical Course of SCLC. CancerNetwork. https://www.cancernetwork.com/view/epidemiology-and-clinical-course-of-sclc 5. Bogart JA, Waqar SN, Mix M (2022) Radiation and systemic therapy for limited-stage small-cell lung cancer. J Clin Oncol 40(6):661–670. https://doi.org/10.1200/JCO.21.01639
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|